Ionis Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 06/04/2023
Ionis Pharmaceuticals Stock Forecast and Price Target
The average price target of $50.00 for Ionis Pharmaceuticals's stock set by six distinguished analysts in recent weeks would represent a potential upside of approximately 19.76% from the last closing price in June, 2023 if reached by the end of the year. This potential increase is based on a high estimate of $92.00 and a low estimate of $26.00. If you are interested in IONS stock, it is important to also consider its competitors.
19.76% Upside
Ionis Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's Price has decreased by 62.56% In the last two years, from $32.85 to $12.30. In the next year, analysts predict that Fair Value will jump to $44.43 – up 261.19% from the current level. Looking ahead to eight years, experts forecast that Fair Value will grow by 658.93%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PFE Stock Forecast | Pfizer Inc | Outperform |
3
|
$38.36 | Buy/Sell | $47.96 | 37.25% |
| AMGN Stock Forecast | Amgen Inc | Hold |
7
|
$218.07 | Buy/Sell | $268.00 | 27.48% |
| SAN Stock Forecast | Sanofi | Outperform |
10
|
91.12€ | Buy/Sell | 108.44€ | 20.72% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$739.95 | Buy/Sell | $796.73 | 5.68% |
| MRNA Stock Forecast | Moderna | Outperform |
11
|
$130.51 | Buy/Sell | $0.00 | 63.59% |
Ionis Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's Revenue has decreased by 27.81% In the last two years, from $1.12B to $810.46M. In the following year, the 20 analysts surveyed believe that Ionis Pharmaceuticals's Revenue will decrease by 17.80%, reaching $666.18M. Looking ahead to eight years, experts forecast that Revenue will grow by 326.99%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| 4568 Stock Forecast | Daiichi Sankyo Company | Outperform |
18
|
¥4.07k | Buy/Sell | ¥0.00 | 35.30% |
| SGEN Stock Forecast | Seagen | Hold |
6
|
$195.38 | Buy/Sell | $167.40 | -20.67% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$193.67 | Buy/Sell | $244.18 | 29.60% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$93.36 | Buy/Sell | $115.45 | 28.53% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$62.54 | Buy/Sell | $88.18 | 37.51% |
| SRPT Stock Forecast | Sarepta Therapeutics | Outperform |
6
|
$125.16 | Buy/Sell | $139.65 | 21.44% |
Ionis Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last two years, Ionis Pharmaceuticals's Free Cash Flow has decreased by 94.01%, from $314.72M to $18.84M. For the next year, 4 analysts project Ionis Pharmaceuticals's Free Cash Flow to drop by 1828.13%, reaching $-325.58M. Over the next eight years, experts anticipate that Free Cash Flow growth for Ionis Pharmaceuticals will be 5051.27%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JAZZ Stock Forecast | Jazz Pharmaceuticals | Outperform |
14
|
$158.79 | Buy/Sell | $0.00 | 25.95% |
| EXEL Stock Forecast | Exelixis | Outperform |
16
|
$19.19 | Buy/Sell | $24.94 | 30.28% |
| 4516 Stock Forecast | Nippon Shinyaku | Outperform |
18
|
¥7.07k | Buy/Sell | ¥0.00 | 55.59% |
Ionis Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030
In the last two years, Ionis Pharmaceuticals has seen a decline in its Net Income, from $278.14M to $-28.60M – a 110.28% decrease. In the next year, analysts believe that Net Income will reach $-263.01M – an increase of 819.62%. By 2030, professionals believe that Ionis Pharmaceuticals's Net Income will have decreased by 1596.08%, falling to $427.88M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DCPH Stock Forecast | Deciphera Pharmaceuticals | Hold |
6
|
$14.08 | Buy/Sell | $0.00 | -28.98% |
| STOK Stock Forecast | Stoke Therapeutics | Buy |
4
|
$12.17 | Buy/Sell | $61.44 | 327.28% |
| DYN Stock Forecast | Dyne Therapeutics | Buy |
5
|
$12.81 | Buy/Sell | $0.00 | 79.55% |
Ionis Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Ionis Pharmaceuticals's EBITDA has fallen from $382.56M to $14.26M – a 96.27% decrease. According to 4 prominent analysts, Ionis Pharmaceuticals's EBITDA will fall by 1411.08% in the next year, reaching $-186.96M. By 2030, professionals believe that Ionis Pharmaceuticals's EBITDA will decrease by 1688.40%, reaching $-226.51M – a concerning trend for the company.
Ionis Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's EBIT has decreased In the last two years, from $368.11M to $-3.58M – a 100.97% drop. In the next year, analysts are expecting an increase in EBIT, predicting it will reach $-383.30M – an increase of 10606.70%. In 2030, professionals predict that Ionis Pharmaceuticals's EBIT will decrease by 45803.07%, to $1.64B.
Ionis Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
Ionis Pharmaceuticals's EPS has decreased by 62.56% In the last two years, from $2.19 to $0.82. In the following year, the 8 analysts surveyed believe that Ionis Pharmaceuticals's EPS will decrease by 326.83%, reaching $-1.86. Looking ahead to eight years, experts forecast that EPS will grow by 751.22%.
Site Navigation
.jpg)